Medical - Instruments & Supplies
Compare Stocks
5 / 10Stock Comparison
KRMD vs LMAT vs ATRC vs MMSI vs ITGR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Devices
KRMD vs LMAT vs ATRC vs MMSI vs ITGR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $207M | $2.46B | $1.41B | $3.72B | $3.03B |
| Revenue (TTM) | $43M | $256M | $552M | $1.54B | $1.85B |
| Net Income (TTM) | $-2M | $62M | $-5M | $139M | $142M |
| Gross Margin | 60.1% | 72.4% | 75.5% | 48.7% | 23.3% |
| Operating Margin | -5.1% | 28.5% | -0.4% | 12.2% | 10.4% |
| Forward P/E | — | 37.2x | 370.7x | 15.5x | 13.5x |
| Total Debt | $3M | $186M | $88M | $898M | $1.40B |
| Cash & Equiv. | $9M | $28M | $167M | $449M | $17M |
KRMD vs LMAT vs ATRC vs MMSI vs ITGR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| KORU Medical System… (KRMD) | 100 | 43.9 | -56.1% |
| LeMaitre Vascular, … (LMAT) | 100 | 401.3 | +301.3% |
| AtriCure, Inc. (ATRC) | 100 | 58.1 | -41.9% |
| Merit Medical Syste… (MMSI) | 100 | 138.5 | +38.5% |
| Integer Holdings Co… (ITGR) | 100 | 111.0 | +11.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KRMD vs LMAT vs ATRC vs MMSI vs ITGR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
KRMD is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 11.2% 10Y total return vs LMAT's 6.1%
- 22.2% revenue growth vs ITGR's 7.6%
- +63.2% vs MMSI's -33.8%
LMAT carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 15 yrs, beta 0.57, yield 0.7%
- Lower volatility, beta 0.57, Low D/E 47.2%, current ratio 12.89x
- PEG 1.92 vs ITGR's 3.08
- Beta 0.57, yield 0.7%, current ratio 12.89x
ATRC ranks third and is worth considering specifically for growth exposure.
- Rev growth 14.9%, EPS growth 74.7%, 3Y rev CAGR 17.4%
MMSI lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, ITGR doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 22.2% revenue growth vs ITGR's 7.6% | |
| Value | Lower P/E (37.2x vs 370.7x) | |
| Quality / Margins | 24.3% margin vs KRMD's -5.3% | |
| Stability / Safety | Beta 0.57 vs KRMD's 1.15 | |
| Dividends | 0.7% yield; 15-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +63.2% vs MMSI's -33.8% | |
| Efficiency (ROA) | 10.3% ROA vs KRMD's -8.3%, ROIC 9.7% vs -19.5% |
KRMD vs LMAT vs ATRC vs MMSI vs ITGR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
KRMD vs LMAT vs ATRC vs MMSI vs ITGR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LMAT leads in 5 of 6 categories
ITGR leads 1 • KRMD leads 0 • ATRC leads 0 • MMSI leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
LMAT leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ITGR is the larger business by revenue, generating $1.8B annually — 42.8x KRMD's $43M. LMAT is the more profitable business, keeping 24.3% of every revenue dollar as net income compared to KRMD's -5.3%. On growth, KRMD holds the edge at +22.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $43M | $256M | $552M | $1.5B | $1.8B |
| EBITDAEarnings before interest/tax | -$1M | $81M | $13M | $290M | $328M |
| Net IncomeAfter-tax profit | -$2M | $62M | -$5M | $139M | $142M |
| Free Cash FlowCash after capex | $179,290 | $79M | $54M | $274M | $168M |
| Gross MarginGross profit ÷ Revenue | +60.1% | +72.4% | +75.5% | +48.7% | +23.3% |
| Operating MarginEBIT ÷ Revenue | -5.1% | +28.5% | -0.4% | +12.2% | +10.4% |
| Net MarginNet income ÷ Revenue | -5.3% | +24.3% | -0.8% | +9.0% | +7.7% |
| FCF MarginFCF ÷ Revenue | +0.4% | +30.9% | +9.7% | +17.8% | +9.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.1% | +11.2% | +14.3% | +7.8% | +0.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +33.3% | +41.7% | +101.6% | +38.8% | +172.7% |
Valuation Metrics
ITGR leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 29.3x trailing earnings, MMSI trades at a 32% valuation discount to LMAT's 42.8x P/E. Adjusting for growth (PEG ratio), LMAT offers better value at 2.21x vs ITGR's 6.91x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $207M | $2.5B | $1.4B | $3.7B | $3.0B |
| Enterprise ValueMkt cap + debt − cash | $201M | $2.6B | $1.3B | $4.2B | $4.4B |
| Trailing P/EPrice ÷ TTM EPS | -77.76x | 42.82x | -115.83x | 29.26x | 30.42x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 37.17x | 370.67x | 15.46x | 13.55x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.21x | — | — | 6.91x |
| EV / EBITDAEnterprise value multiple | — | 33.39x | 77.75x | 13.06x | 13.15x |
| Price / SalesMarket cap ÷ Revenue | 5.02x | 9.85x | 2.63x | 2.45x | 1.64x |
| Price / BookPrice ÷ Book value/share | 12.03x | 6.29x | 2.70x | 2.38x | 1.79x |
| Price / FCFMarket cap ÷ FCF | — | 33.01x | 29.15x | 17.24x | 28.78x |
Profitability & Efficiency
LMAT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
LMAT delivers a 16.2% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-14 for KRMD. ATRC carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to ITGR's 0.80x. On the Piotroski fundamental quality scale (0–9), LMAT scores 7/9 vs ITGR's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -13.6% | +16.2% | -1.0% | +8.9% | +8.2% |
| ROA (TTM)Return on assets | -8.3% | +10.3% | -0.7% | +5.2% | +4.2% |
| ROICReturn on invested capital | -19.5% | +9.7% | -0.6% | +7.2% | +5.4% |
| ROCEReturn on capital employed | -14.9% | +12.3% | -0.6% | +7.9% | +6.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 5 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.21x | 0.47x | 0.18x | 0.57x | 0.80x |
| Net DebtTotal debt minus cash | -$5M | $157M | -$79M | $450M | $1.4B |
| Cash & Equiv.Liquid assets | $9M | $28M | $167M | $449M | $17M |
| Total DebtShort + long-term debt | $3M | $186M | $88M | $898M | $1.4B |
| Interest CoverageEBIT ÷ Interest expense | — | 24.99x | 0.47x | 10.74x | 5.07x |
Total Returns (Dividends Reinvested)
LMAT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LMAT five years ago would be worth $21,818 today (with dividends reinvested), compared to $3,579 for ATRC. Over the past 12 months, KRMD leads with a +63.2% total return vs MMSI's -33.8%. The 3-year compound annual growth rate (CAGR) favors LMAT at 18.2% vs ATRC's -16.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -20.9% | +34.9% | -29.2% | -27.9% | +14.5% |
| 1-Year ReturnPast 12 months | +63.2% | +33.3% | -8.3% | -33.8% | -26.1% |
| 3-Year ReturnCumulative with dividends | +13.3% | +65.2% | -41.8% | -26.5% | +8.8% |
| 5-Year ReturnCumulative with dividends | +24.0% | +118.2% | -64.2% | -3.6% | -7.5% |
| 10-Year ReturnCumulative with dividends | +1116.4% | +608.6% | +95.1% | +214.6% | +165.1% |
| CAGR (3Y)Annualised 3-year return | +4.2% | +18.2% | -16.5% | -9.8% | +2.9% |
Risk & Volatility
LMAT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LMAT is the less volatile stock with a 0.57 beta — it tends to amplify market swings less than KRMD's 1.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LMAT currently trades 91.4% from its 52-week high vs MMSI's 62.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.15x | 0.57x | 1.03x | 0.71x | 0.72x |
| 52-Week HighHighest price in past year | $6.61 | $118.12 | $43.18 | $100.19 | $123.78 |
| 52-Week LowLowest price in past year | $2.63 | $78.35 | $26.62 | $59.74 | $62.00 |
| % of 52W HighCurrent price vs 52-week peak | +67.2% | +91.4% | +64.4% | +62.2% | +71.0% |
| RSI (14)Momentum oscillator 0–100 | 42.9 | 48.3 | 45.0 | 34.9 | 50.9 |
| Avg Volume (50D)Average daily shares traded | 138K | 244K | 669K | 769K | 628K |
Analyst Outlook
LMAT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: KRMD as "Buy", LMAT as "Buy", ATRC as "Buy", MMSI as "Buy", ITGR as "Buy". Consensus price targets imply 82.3% upside for ATRC (target: $51) vs -5.9% for LMAT (target: $102). LMAT is the only dividend payer here at 0.73% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $7.00 | $101.50 | $50.67 | $95.00 | $98.00 |
| # AnalystsCovering analysts | 5 | 20 | 19 | 13 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | +0.7% | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | 15 | — | — | — |
| Dividend / ShareAnnual DPS | — | $0.79 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.8% | 0.0% | +1.7% |
LMAT leads in 5 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ITGR leads in 1 (Valuation Metrics).
KRMD vs LMAT vs ATRC vs MMSI vs ITGR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is KRMD or LMAT or ATRC or MMSI or ITGR a better buy right now?
For growth investors, KORU Medical Systems, Inc.
(KRMD) is the stronger pick with 22. 2% revenue growth year-over-year, versus 7. 6% for Integer Holdings Corporation (ITGR). Merit Medical Systems, Inc. (MMSI) offers the better valuation at 29. 3x trailing P/E (15. 5x forward), making it the more compelling value choice. Analysts rate KORU Medical Systems, Inc. (KRMD) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — KRMD or LMAT or ATRC or MMSI or ITGR?
On trailing P/E, Merit Medical Systems, Inc.
(MMSI) is the cheapest at 29. 3x versus LeMaitre Vascular, Inc. at 42. 8x. On forward P/E, Integer Holdings Corporation is actually cheaper at 13. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: LeMaitre Vascular, Inc. wins at 1. 92x versus Integer Holdings Corporation's 3. 08x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — KRMD or LMAT or ATRC or MMSI or ITGR?
Over the past 5 years, LeMaitre Vascular, Inc.
(LMAT) delivered a total return of +118. 2%, compared to -64. 2% for AtriCure, Inc. (ATRC). Over 10 years, the gap is even starker: KRMD returned +1116% versus ATRC's +95. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — KRMD or LMAT or ATRC or MMSI or ITGR?
By beta (market sensitivity over 5 years), LeMaitre Vascular, Inc.
(LMAT) is the lower-risk stock at 0. 57β versus KORU Medical Systems, Inc. 's 1. 15β — meaning KRMD is approximately 101% more volatile than LMAT relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 80% for Integer Holdings Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — KRMD or LMAT or ATRC or MMSI or ITGR?
By revenue growth (latest reported year), KORU Medical Systems, Inc.
(KRMD) is pulling ahead at 22. 2% versus 7. 6% for Integer Holdings Corporation (ITGR). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -15. 0% for Integer Holdings Corporation. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — KRMD or LMAT or ATRC or MMSI or ITGR?
LeMaitre Vascular, Inc.
(LMAT) is the more profitable company, earning 23. 1% net margin versus -6. 4% for KORU Medical Systems, Inc. — meaning it keeps 23. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LMAT leads at 27. 2% versus -7. 2% for KRMD. At the gross margin level — before operating expenses — ATRC leads at 74. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is KRMD or LMAT or ATRC or MMSI or ITGR more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, LeMaitre Vascular, Inc. (LMAT) is the more undervalued stock at a PEG of 1. 92x versus Integer Holdings Corporation's 3. 08x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Integer Holdings Corporation (ITGR) trades at 13. 5x forward P/E versus 370. 7x for AtriCure, Inc. — 357. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 82. 3% to $50. 67.
08Which pays a better dividend — KRMD or LMAT or ATRC or MMSI or ITGR?
In this comparison, LMAT (0.
7% yield) pays a dividend. KRMD, ATRC, MMSI, ITGR do not pay a meaningful dividend and should not be held primarily for income.
09Is KRMD or LMAT or ATRC or MMSI or ITGR better for a retirement portfolio?
For long-horizon retirement investors, LeMaitre Vascular, Inc.
(LMAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57), 0. 7% yield, +608. 6% 10Y return). Both have compounded well over 10 years (LMAT: +608. 6%, ATRC: +95. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between KRMD and LMAT and ATRC and MMSI and ITGR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KRMD is a small-cap high-growth stock; LMAT is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock; MMSI is a small-cap quality compounder stock; ITGR is a small-cap quality compounder stock. LMAT pays a dividend while KRMD, ATRC, MMSI, ITGR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.